saplin

UTI - Healthcare Fund

UTI - Healthcare Fund (Direct, Growth): saplin Score 7.5/10 (Neutral) among 14 Sectoral/Thematic funds. 3Y return 23.9% a year vs 21.9% category median, expense ratio 1.31%. Returns that beat most peers, but higher costs than most peers. NAV ₹400.53 on 11 Nov 2026.

Loading the full analysis…

Questions about UTI - Healthcare Fund

What is the expense ratio of UTI - Healthcare Fund?

The Direct plan's total expense ratio is 1.31% a year, against a median of 1.04% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

Who manages UTI - Healthcare Fund?

Kamal Gada (since 2 May 2022).

What are the top holdings of UTI - Healthcare Fund?

Sun Pharmaceutical Industries 7.44%, Divi's Laboratories 6.46%, Dr. Reddy's Laboratories 5.78%, Ajanta Pharma 4.29%, Max Healthcare Institute 4.20% of the portfolio, as of 31 Oct 2026.

What returns has UTI - Healthcare Fund given?

1 year: 22.6% (category median 21.9%); 3 years: 23.9% a year (category median 21.9%); 5 years: 17.7% a year (category median 16.8%). Past returns do not predict future ones.

How big is UTI - Healthcare Fund?

About ₹1,399 cr (AMFI's average for the latest quarter).

How does UTI - Healthcare Fund score?

7.5 out of 10 (Neutral) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.

More on UTI - Healthcare